Survival Benefit of Sequential Curative Treatment for TACE Suitable BCLC Stage B HCC Patients

Abstract To clarify the survival benefit of sequential curative treatment post transcatheter arterial chemoembolization (TACE) for Barcelona Clinic Liver Cancer (BCLC) stage B hepatocellular carcinoma (HCC), we retrospectively analyzed HCC patients at a hospital. From July 2017 to July 2020, 787 treatment-naïve HCC patients underwent initial treatment; 77 (9.8%) meeting inclusion criteria were enrolled. Their initial treatments were TACE only (n=68, 88.3%) or TACE with other treatments (n=9, 11.7%). Median survival of the TACE-only group was 30 months. Treatment response was evaluated after 2 or 3 consecutive TACEs for patients (54/68, 79.4%) with available pre-/post-TACE computerized tomography (CT) or magnetic resonance imaging (MRI). Treatment responses was divided into 4 groups: complete (n=14, 26%, group (Gr) 1), incomplete without new tumor growth (n=28, 52.0%, Gr2), incomplete with new growth (n=6, 11%, Gr3), and progression (n=6, 11%, Gr4). Of Gr2, further treatment after TACE were had radiofrequency ablation (n=13, Gr2a), TACE (n=9, Gr2b), other modalities (n=6, Gr2c). Gr2a's median survival was longer than Gr2b's (>60 vs. 20 months, p=0.007). Nine patients in Gr2a (69%, 9/13) achieved a complete response, but none in Gr2b (p=0.001). Conclusively, in TACE-suitable BCLC stage B HCC patients, a partial response without new tumor growth can serve as an indicator of treatment effectiveness following initial TACE treatment. This can facilitate the selection of appropriate candidates to receive RFA, potentially resulting in improved patient survival.